Neuropsychological and pharmacokinetic assessment of hospice inpatients receiving morphine

Journal of Pain and Symptom Management

Volumn 16, Issue 2, 1998, Pages 112-120

  Wood, Michael M ^a,e   Ashby, Michael A ^b,d   Somogyi, Andrew A ^c   Fleming, Beverley G ^c  

^a FLINDERS UNIVERSITY   (Australia)

^b ROYAL ADELAIDE HOSPITAL   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d MONASH MEDICAL CENTRE   (Australia)

^e Liverpool Health Service   (Australia)

Author keywords

Cognitive; Function; Morphine; Palliative care

Indexed keywords

CREATININE; GAMMA GLUTAMYLTRANSFERASE; MORPHINE; MORPHINE 3 GLUCURONIDE; MORPHINE 6 GLUCURONIDE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER PAIN; CLINICAL ARTICLE; COGNITIVE DEFECT; DRUG BLOOD LEVEL; DRUG METABOLISM; FEMALE; HUMAN; KIDNEY FUNCTION; MALE; NAUSEA; NEUROPSYCHOLOGICAL TEST; ORAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; TERMINAL CARE; VOMITING;

ADULT; AGED; ANALGESICS, OPIOID; EVALUATION STUDIES; FEMALE; HOSPICE CARE; HUMANS; MALE; MIDDLE AGED; MORPHINE; NEUROPSYCHOLOGICAL TESTS;

EID: 0032143485     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(98)00043-8     Document Type: Article

References (44)

1. 1. O'Neill WM. The cognitive and psychomotor effects of opioid drugs in cancer pain management. In: Cancer surveys, Vol 21. Hanks GW, ed. Palliative medicine: problem areas in pain and symptom management. New York: Cold Spring Harbor Laboratory Press, 1994.
2. 2. Hartman DE. Neuropsychological toxicology: identification and assessment of human neurotoxic syndromes, 2nd ed. New York: Plenum, 1995.
3. 3. Fields S, Fullerton J. Influence of heroin addiction on neuropsychological functioning. J Consult Clin Psychol 1975; 43:114.
4. 4. Reitan R, Wolfson D. The Halstead-Reitan Neuropsychological Battery. Theory and clinical interpretation. Tuscan, AZ: Neuropsychology Press, 1993.
5. 5. Kerr B, Hill H, Coda B, et al. Concentration-related effects of morphine on cognition and motor control in human subjects. Neuropsychopharmacol 1991; 5:157-166.
6. 6. Caraceni A, Martini C, Conno F, Ventafidda V. Organic brain syndromes and opioid administration for cancer pain. J Pain Symptom Manage 1993;9: 527-533.
7. 7. Wood MM, Cousins MJ. Iatrogenic neurotoxicity in cancer patients. Pain 1989;39:1-3.
8. 8. Bruera E, Macmillan K, Hanson J, MacDonald RN. The cognitive effects of the administration of narcotic analgesics in patients with cancer pain. Pain 1989;39:13-16.
9. 9. Sjøgren P and Banning A. Pain, sedation and reaction time during long-term treatment of cancer patients with oral and epidural opioids. Pain 1989; 39:5-11.
10. 10. Vainio A, Ollila J, Matikainene E, Rosenberg P, Kalso E. Driving ability in cancer patients receiving long-term morphine analgesia. Lancet 1995;346: 667-670.
11. 11. Hanks GW. Morphine sans morpheus [Commentary]. Lancet 1995;346:652-653.
12. 12. Stedeford A. Confusional states in advanced cancer - A flow diagram. Palliat Med 1991;5:256-261.
13. 13. Bruera E, Miller L, McCallion J, Macmillan K, Krefting L, Hanson J. Cognitive failure in patients with terminal cancer: a prospective study. J Pain Symptom Manage 1992;7:192-195.
14. 14. Bruera E, Fainsinger RL, Miller MJ. The assessment of pain intensity in patients with cognitive failure: a preliminary report. J Pain Symptom Manage 1992;7:267-270.
15. 15. Ming Yue, Fainsinger R, Bruera E. Cognitive impairment in a patient with a normal mini-mental state examination (MMSE). J Pain Symptom Manage 1994;9:51-53.
16. 16. Bruera E, Franco JJ, Maltoni M, Watanabe S, Suarez-Almazor M. Changing pattern of agitated impaired mental status in patients with advanced cancer: association with cognitive monitoring, hydration, and opioid rotation. J Pain Symptom Manage 1995;10:287-291.
17. 17. Pereira J, Hanson J, Bruera E. The frequency and clinical course of cognitive impairment in terminal cancer patients [Abstract]. 11th International Congress on Care of the Terminally III. Montreal, September 1996. J Palliat Care 1996;12:64.
18. 18. Burke A. Update on terminal restlessness. Med J Aust 1997;166:39-42.
19. 19. Galer BS, Coyle N, Pasternak GW, Portenoy RK. Individual variability in the response to different opioids: report of five cases. Pain 1992;49:87-91.
20. 20. de Stoutz ND, Bruera E, Suarez-Almazor M. Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 1995;10:378-384.
21. 21. Paix A, Coleman A, Lees J, Grigson J, Brooksbank M, Thorne D, Ashby M. Subcutaneous fentanyl and sufentanil infusion substitution for morphine intolerance in cancer pain management. Pain 1995;63: 263-269.
22. 22. Maddocks I, Somogyi A, Abbott F, Hayball P, Parker D. Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J Pain Symptom Manage 1996;12:182-189.
23. 23. Wood MM, Ashby M, Fleming B, Somogyi A. The neuropsychological correlates of morphine plasma concentrations in terminally ill patients. 7th World Congress on Pain. Paris, August 1993.
24. 24. Wood MM, Ashby M, Fleming B, Somogyi A. The neuropsychological correlates of plasma morphine concentrations in terminally ill patients. National Hospice and Palliative Care Conference. Melbourne, 1993.
25. 25. Smith GD and Smith MT. Morphine-3-glucuronide: evidence to support its putative role in the development of tolerance to the antinociceptive effects of morphine in the rat. Pain 1995;62:51-60.
26. 26. Milne RW, Nation RL, Somogyi AA. The disposition of morphine and its 3-and 6-glucuronide metabolites in humans and animals, and the importance of the metabolites to the pharmacological effects of morphine. Drug Metab Rev 1996;28:345-472.
27. 27. Ashby M, Fleming B, Wood M, Somogyi A. Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice patients. J Pain Symptom Manage 1997;14:157-167.
28. 28. Ashby M, Fleming BG, Crugten J, Wood MM, Somogyi A. Plasma morphine, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) concentrations in hospice patients receiving morphine for cancer pain. National Hospice and Palliative Care Conference. Melbourne, October 1993.
29. 29. Ashby M, Fleming BG, van Crugten J, Wood MM, Somogyi A. Plasma morphine, morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) concentrations in hospice patients receiving morphine for cancer pain: absence of relationship to opioid side effects. 7th World Congress on Pain. Paris, August 1993.
30. 30. Milne RW, Nation RI, Reynolds GD, Somogyi AA, Van Crugten JT. High performance liquid chromatographic determination of morphine and its 3-and 6-glucuronide metabolites: improvements to the method and application to stability studies. J Chromatogr 1991;565:457-464.
31. 31. Nelson H. The National Adult Reading Test (NART): test manual. Windsor, UK: NFER-Nelson, 1982.
32. 32. Crawford, JR. Estimation of premorbid intelligence: a review of recent developments. In: Crawford JR, Parker DM, eds. Developments in clinical and experimental neuropsychology. New York: Plenum Publishing, 1989.
33. 33. Smith A. Symbol Digit Modalities Test (SDMT) manual (revised). Los Angeles: Western Psychological Services. 1982.
34. 34. Wechsler D. WAIS-R manual. New York: The Psychological Corporation. 1981.
35. 35. Williams M. Mental testing in clinical practice. Oxford: Penguin, 1965.
36. 36. Reitan R. Validity of the Trail Making Test as an indication of organic brain damage. Percept Motor Skills 1958;8:271-276.
37. 37. Folstein MF, Folstein SE, McHugh PR. MiniMental State. J Psychiat Res 1975;12:189-198.
38. 38. Folstein MF, Petting JH, Lobo A, Niaz U, Capozzoli KD. Cognitive assessment of cancer patients. Cancer 1984;53:2250-2257.
39. 39. Knights EB, Folstein MF. Unsuspected emotional and cognitive disturbance in medical patients. Ann Intern Med 1997;87:723-734.
40. 40. Anthony JC, Le Resche L, Niaz U, von Korff MR, Folstein MF. Limits of the Mini-Mental State as a Screening Test for Dementia and Delirium Among Hospital Patients. Psychol Med 1982;12:397-408.
41. 41. Collin E, Poulain P, Gauiain-Piquard A, Petit G, Pichard-Leandri E. Is disease progression the major factor in morphine 'tolerance' in cancer pain treatment? Pain 1993;55:319-326.
42. 42. Portenoy RK. Tolerance to opioid analgesics: clinical aspects. In: Cancer Surveys, Vol. 21. Hanks GW, ed. Palliative medicine problem areas in pain and symptom management. New York: Cold Spring Harbor Laboratory Press, 1994.
43. 43. Olsen AK, Sjøgren P. Neurotoxic effects of opioids. Eur J Palliat Care 1996;3:139-142.
44. 44. Smith MJ, Breitbart WS, Platt MM. A critique of instruments and methods to detect, diagnose, and rate delirium. J Pain Symptom Manage 1995;10:35-77.